Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of GEC255 Oral Tablets in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

NCT05768321 is registered in ClinicalTrials.gov with GenEros Biopharma Hangzhou Ltd as lead sponsor.

NCT NCT05768321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05768321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of GEC255 Oral Tablets in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
Lead sponsor
GenEros Biopharma Hangzhou Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
November 4, 2021
Completion date
May 30, 2024
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors